Find clinical trials for Lung Cancer in London, England
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Lung Cancer trials near London, England, GBR:
a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung...
Phase 2
London, England, United Kingdom and 71 other locations
The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tole...
Phase 2
London, United Kingdom and 52 other locations
with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....
Phase 3
London, United Kingdom and 210 other locations
This is a Phase II, multi-site, open-label, parallel group study in participants with untreated extended-stage small-cell lung cancer...
Phase 2
London, London, City of, England and 64 other locations
This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...
Phase 2
London, United Kingdom and 123 other locations
with advanced/metastatic or relapsed/progressive small cell lung cancer (SCLC) and non small cell lung cancer (NS...
Phase 1, Phase 2
London, United Kingdom and 87 other locations
The goal of this platform clinical trial is to test how well novel treatment combinations work in participants with lung cancer. Su ...
Phase 2
London, United Kingdom and 88 other locations
The goal of this clinical trial is to learn if the FlexAblate™ Ablation System works to treat a lung cancer nodules and it will als...
London, United Kingdom and 2 other locations
KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung...
Phase 3
London, United Kingdom and 156 other locations
The main aim of this study is to:* evaluate safety and efficacy (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST 1.1\]...
Phase 2
London, United Kingdom and 80 other locations
Clinical trials
Research sites
Resources
Legal